<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448368</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-111</org_study_id>
    <nct_id>NCT02448368</nct_id>
  </id_info>
  <brief_title>RDEA3170 Tablet and Capsule Bioavailability Study</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules
      compared with RDEA3170 tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">January 29, 2016</completion_date>
  <primary_completion_date type="Actual">June 26, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>Cmax is the maximum observed concentration of a drug after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>Tmax is the time of occurrence of cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2)</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>t1/2 is a measure of apparent terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>Cmax is the maximum observed concentration of a drug after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) Profile of RDEA3170</measure>
    <time_frame>Day -1, 1, 5, 9, 13, 17</time_frame>
    <description>Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 5 mg (FN24), administered in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 10 mg (FN25), administered in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 10 mg (FN26), administered in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170,10 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 2.5 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>Treatment E</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 5 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 10 mg</intervention_name>
    <description>Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.</description>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_label>Treatment J</arm_group_label>
    <other_name>Cohort 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 2.5 mg</intervention_name>
    <description>Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.</description>
    <arm_group_label>Treatment K</arm_group_label>
    <other_name>Cohort 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved, and is
             willing to provide written informed consent before the first study-related activity.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2.

          -  Subject has a Screening serum urate level of 4 to 7 mg/dL.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has undergone major surgery within 3 months prior to Screening.

          -  Subject donated blood or experienced significant blood loss within 12 weeks prior to
             Day 1 or gave a plasma donation within 4 weeks prior to Day 1.

          -  Subject has clinically unacceptable physical examination, per the Investigator's
             judgment.

          -  Subject has clinically relevant abnormalities in blood pressure, heart rate, or body
             temperature, per the Investigator's judgment.

          -  Subject has Screening clinical safety laboratory parameters (serum chemistry [other
             than serum creatinine and serum urate], hematology, coagulation or urinalysis) that
             are outside the normal limits and are considered clinically significant by the
             Investigator.

          -  Subject has a serum creatinine value above the upper limit of normal at the Screening
             visit.

          -  Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the
             Investigator's judgment.

          -  Subject has a history of cardiac abnormalities

          -  Subject cannot swallow multiple tablets or capsules.

          -  Subject has received any strong or moderate enzyme-inducing drug or product within 2
             months prior to Day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <results_first_submitted>June 12, 2017</results_first_submitted>
  <results_first_submitted_qc>November 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2018</results_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verinurad</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>35 participants were randomized</recruitment_details>
      <pre_assignment_details>Twenty subjects were randomized to 1 of 10 treatment sequences in Cohort 1 with single doses. Fifteen subjects were randomized to 1 of 3 treatment sequences (IJK, JKI, and KIJ) in optional Cohort 3, with single doses occurring on Days 1, 5, and 9. The optional Cohort 2 to evaluate RDEA3170 capsules, 5 mg FN23 was not conducted per Sponsor decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Sequence ABECD (Days 1, 5, 9, 13, and 17)</title>
          <description>5 mg FN24 capsules, fasted; 5 mg FN24 capsules, fed; 10 mg FN17 tablets, fasted; 10 mg FN25 capsules, fasted; 10 mg FN25 capsules, fed</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Sequence AEBDC (Days 1, 5, 9, 13, and 17)</title>
          <description>5 mg FN24 capsules, fasted; 10 mg FN17 tablets, fasted; 5 mg FN24 capsules, fed; 10 mg FN25 capsules, fed; 10 mg FN25 capsules, fasted</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Sequence EADBC (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN17 tablets, fasted; 5 mg FN24 capsules, fasted; 10 mg FN25 capsules, fed; 5 mg FN24 capsules, fed; 10 mg FN25 capsules, fasted</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: Sequence EDACB (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN17 tablets, fasted; 10 mg FN25 capsules, fed; 5 mg FN24 capsules, fasted; 10 mg FN25 capsules, fasted; 5 mg FN24 capsules, fed</description>
        </group>
        <group group_id="P5">
          <title>Cohort 1: Sequence DECAB (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN25 capsules, fed; 10 mg FN17 tablets, fasted; 10 mg FN25 capsules, fasted; 5 mg FN24 capsules, fasted; 5 mg FN24 capsules, fed</description>
        </group>
        <group group_id="P6">
          <title>Cohort 1: Sequence BACED (Days 1, 5, 9, 13, and 17)</title>
          <description>5 mg FN24 capsules, fed; 5 mg FN24 capsules, fasted; 10 mg FN25 capsules, fasted; 10 mg FN17 tablets, fasted; 10 mg FN25 capsules, fed</description>
        </group>
        <group group_id="P7">
          <title>Cohort 1: Sequence BCADE (Days 1, 5, 9, 13, and 17)</title>
          <description>5 mg FN24 capsules, fed; 10 mg FN25 capsules, fasted; 5 mg FN24 capsules, fasted; 10 mg FN25 capsules, fed; 10 mg FN17 tablets, fasted</description>
        </group>
        <group group_id="P8">
          <title>Cohort 1: Sequence CBDAE (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN25 capsules, fasted; 5 mg FN24 capsules, fed; 10 mg FN25 capsules, fed; 5 mg FN24 capsules, fasted; 10 mg FN17 tablets, fasted</description>
        </group>
        <group group_id="P9">
          <title>Cohort 1: Sequence CDBEA (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN25 capsules, fasted; 10 mg FN25 capsules, fed; 5 mg FN24 capsules, fed; 10 mg FN17 tablets, fasted; 5 mg FN24 capsules, fasted</description>
        </group>
        <group group_id="P10">
          <title>Cohort 1: Sequence DCEBA (Days 1, 5, 9, 13, and 17)</title>
          <description>10 mg FN25 capsules, fed; 10 mg FN25 capsules, fasted; 10 mg FN17 tablets, fasted; 5 mg FN24 capsules, fed; 5 mg FN24 capsules, fasted</description>
        </group>
        <group group_id="P11">
          <title>Cohort 3: Sequence IJK (Days 1, 5, and 9)</title>
          <description>10 mg FN26 capsules, fasted; 10 mg FN26 capsules, fed; 10 mg FN17 tablets, fasted</description>
        </group>
        <group group_id="P12">
          <title>Cohort 3: Sequence JKI (Days 1, 5, and 9)</title>
          <description>10 mg FN26 capsules, fed; 10 mg FN17 tablets, fasted; 10 mg FN26 capsules, fasted</description>
        </group>
        <group group_id="P13">
          <title>Cohort 3: Sequence KIJ (Days 1, 5, and 9)</title>
          <description>10 mg FN17 tablets, fasted; 10 mg FN26 capsules, fasted; 10 mg FN26 capsules, fed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Treatment A: RDEA3170 capsules, 5 mg (FN24), administered in the fasted state. Treatment B: RDEA3170 capsules, 5 mg FN24, administered in the fed state (high-fat, high-calorie meal). Treatment C: RDEA3170 capsules, 10 mg (FN25), administered in the fasted state. Treatment D: RDEA3170 capsules, 10 mg FN25, administered in the fed state (high-fat, high-calorie meal). Treatment E: RDEA3170 tablets, 2.5 mg FN17, administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 3 (Optional)</title>
          <description>Treatment I: RDEA3170 capsules, 10 mg (FN26), administered in the fasted state. Treatment J: RDEA3170 capsules, 10 mg FN26, administered in the fed state (high-fat, high-calorie meal).
Treatment K: RDEA3170 tablets, 2.5 mg FN17, administered as 10 mg (4 × 2.5 mg), in the fasted state</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="8.9"/>
                    <measurement group_id="B2" value="41" spread="12.0"/>
                    <measurement group_id="B3" value="38" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Cmax is the maximum observed concentration of a drug after administration</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Cmax is the maximum observed concentration of a drug after administration</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="12.5" upper_limit="17.8"/>
                    <measurement group_id="O2" value="23.4" lower_limit="19.3" upper_limit="28.2"/>
                    <measurement group_id="O3" value="12.9" lower_limit="11.2" upper_limit="14.9"/>
                    <measurement group_id="O4" value="14.0" lower_limit="12.1" upper_limit="16.3"/>
                    <measurement group_id="O5" value="13.2" lower_limit="11.2" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the Pharmacokinetics (PK), Pharmacodynamics (PD), and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>232</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>202</ci_lower_limit>
            <ci_upper_limit>266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>181</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>164</ci_lower_limit>
            <ci_upper_limit>200</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>106</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.5</ci_lower_limit>
            <ci_upper_limit>124</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
        <description>Tmax is the time of occurrence of cmax</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
          <group group_id="O8">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
          <description>Tmax is the time of occurrence of cmax</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.05" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" spread="1.69" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O3" value="3.50" spread="1.74" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" spread="1.05" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="2.00" spread="1.54" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" spread="2.71" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O7" value="6.00" spread="2.45" lower_limit="3.00" upper_limit="12.0"/>
                    <measurement group_id="O8" value="3.00" spread="2.66" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</title>
        <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</title>
          <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="80.6" upper_limit="103"/>
                    <measurement group_id="O2" value="185" lower_limit="163" upper_limit="211"/>
                    <measurement group_id="O3" value="109" lower_limit="89.9" upper_limit="132"/>
                    <measurement group_id="O4" value="149" lower_limit="130" upper_limit="171"/>
                    <measurement group_id="O5" value="115" lower_limit="96.9" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>170</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>147</ci_lower_limit>
            <ci_upper_limit>195</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>170</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>146</ci_lower_limit>
            <ci_upper_limit>199</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>129</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114</ci_lower_limit>
            <ci_upper_limit>146</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</title>
        <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O5">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</title>
          <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="84.5" upper_limit="108"/>
                    <measurement group_id="O2" value="192" lower_limit="169" upper_limit="219"/>
                    <measurement group_id="O3" value="121" lower_limit="97.0" upper_limit="150"/>
                    <measurement group_id="O4" value="161" lower_limit="140" upper_limit="184"/>
                    <measurement group_id="O5" value="123" lower_limit="103" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>161</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>139</ci_lower_limit>
            <ci_upper_limit>187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>159</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>135</ci_lower_limit>
            <ci_upper_limit>188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>131</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>116</ci_lower_limit>
            <ci_upper_limit>147</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2)</title>
        <description>t1/2 is a measure of apparent terminal half-life</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
          <group group_id="O8">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2)</title>
          <description>t1/2 is a measure of apparent terminal half-life</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="2.05" lower_limit="11.2" upper_limit="16.5"/>
                    <measurement group_id="O2" value="14.9" spread="1.69" lower_limit="12.6" upper_limit="17.6"/>
                    <measurement group_id="O3" value="14.0" spread="1.74" lower_limit="11.5" upper_limit="17.0"/>
                    <measurement group_id="O4" value="12.9" spread="1.05" lower_limit="10.6" upper_limit="15.6"/>
                    <measurement group_id="O5" value="17.3" spread="1.54" lower_limit="13.4" upper_limit="22.3"/>
                    <measurement group_id="O6" value="14.4" spread="2.71" lower_limit="9.70" upper_limit="21.5"/>
                    <measurement group_id="O7" value="15.8" spread="2.45" lower_limit="11.6" upper_limit="21.5"/>
                    <measurement group_id="O8" value="13.2" spread="2.66" lower_limit="9.44" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
        <description>Cmax is the maximum observed concentration of a drug after administration</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax): Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
          <description>Cmax is the maximum observed concentration of a drug after administration</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="12.5" upper_limit="17.8"/>
                    <measurement group_id="O2" value="15.0" lower_limit="12.6" upper_limit="18.0"/>
                    <measurement group_id="O3" value="23.4" lower_limit="19.3" upper_limit="28.2"/>
                    <measurement group_id="O4" value="23.3" lower_limit="19.2" upper_limit="28.3"/>
                    <measurement group_id="O5" value="14.0" lower_limit="12.1" upper_limit="16.3"/>
                    <measurement group_id="O6" value="16.3" lower_limit="12.9" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>99.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.3</ci_lower_limit>
            <ci_upper_limit>112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>99.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.5</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>116</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.8</ci_lower_limit>
            <ci_upper_limit>143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
        <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
          <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="80.6" upper_limit="103"/>
                    <measurement group_id="O2" value="99.2" lower_limit="86.4" upper_limit="114"/>
                    <measurement group_id="O3" value="185" lower_limit="163" upper_limit="211"/>
                    <measurement group_id="O4" value="192" lower_limit="171" upper_limit="216"/>
                    <measurement group_id="O5" value="149" lower_limit="130" upper_limit="171"/>
                    <measurement group_id="O6" value="172" lower_limit="136" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.3</ci_lower_limit>
            <ci_upper_limit>116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.0</ci_lower_limit>
            <ci_upper_limit>113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>115</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.3</ci_lower_limit>
            <ci_upper_limit>140</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
        <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
        <time_frame>Day 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Capsules</title>
          <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="84.5" upper_limit="108"/>
                    <measurement group_id="O2" value="104" lower_limit="90.5" upper_limit="119"/>
                    <measurement group_id="O3" value="192" lower_limit="169" upper_limit="219"/>
                    <measurement group_id="O4" value="199" lower_limit="177" upper_limit="224"/>
                    <measurement group_id="O5" value="161" lower_limit="140" upper_limit="184"/>
                    <measurement group_id="O6" value="182" lower_limit="142" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.1</ci_lower_limit>
            <ci_upper_limit>116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.6</ci_lower_limit>
            <ci_upper_limit>113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio</param_type>
            <param_value>113</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.3</ci_lower_limit>
            <ci_upper_limit>137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics (PD) Profile of RDEA3170</title>
        <description>Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.</description>
        <time_frame>Day -1, 1, 5, 9, 13, 17</time_frame>
        <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 (but not from pharmacodynamics analysis) following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
          <group group_id="O8">
            <title>Treatment K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD) Profile of RDEA3170</title>
          <description>Serum samples were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours prior to dosing. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. Urine samples (total catch) were collected at the following timepoints in relation to RDEA3170 dosing: Day 1 (Cohort 1 and Cohort 3): -24 to -21, -21 to -18, -18 to -12, and -12 to 0 hours predose. Days 1, 5, and 9 (Cohort 1 and Cohort 3), and Days 13 and 17 (Cohort 1 only): 0 to 3, 3 to 6, 6 to 12, and 12 to 24 hours postdose.</description>
          <population>A subject in Treatment A was excluded from pharmacokinetic (PK) analysis on Day 13 (but not from pharmacodynamics analysis) following oral administration of 5 mg (FN24) capsules under the fasted condition due to a suspected dosing error. There was no evaluable PK available on Day 13 for this subject.</population>
          <units>Percent (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Urate Maximum % Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" spread="2.05"/>
                    <measurement group_id="O2" value="-40.6" spread="1.69"/>
                    <measurement group_id="O3" value="-42.5" spread="1.74"/>
                    <measurement group_id="O4" value="-52.3" spread="1.05"/>
                    <measurement group_id="O5" value="-30.3" spread="1.54"/>
                    <measurement group_id="O6" value="-35.2" spread="2.71"/>
                    <measurement group_id="O7" value="-46.2" spread="2.45"/>
                    <measurement group_id="O8" value="-29.3" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="21.6" lower_limit="33.9" upper_limit="124"/>
                    <measurement group_id="O2" value="92.3" spread="19.0" lower_limit="52.5" upper_limit="132"/>
                    <measurement group_id="O3" value="109" spread="27.8" lower_limit="51.2" upper_limit="168"/>
                    <measurement group_id="O4" value="88.8" spread="13.6" lower_limit="60.3" upper_limit="117"/>
                    <measurement group_id="O5" value="76.8" spread="14.4" lower_limit="46.6" upper_limit="107"/>
                    <measurement group_id="O6" value="49.5" spread="8.22" lower_limit="31.9" upper_limit="67.1"/>
                    <measurement group_id="O7" value="53.7" spread="8.56" lower_limit="35.4" upper_limit="72.1"/>
                    <measurement group_id="O8" value="53.9" spread="10.0" lower_limit="32.4" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Clearance of Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="33.1" lower_limit="10.9" upper_limit="14.6"/>
                    <measurement group_id="O2" value="175" spread="27.2" lower_limit="13.9" upper_limit="17.2"/>
                    <measurement group_id="O3" value="226" spread="48.4" lower_limit="15.3" upper_limit="20.1"/>
                    <measurement group_id="O4" value="216" spread="23.7" lower_limit="15.1" upper_limit="20.9"/>
                    <measurement group_id="O5" value="142" spread="27.1" lower_limit="11.7" upper_limit="15.3"/>
                    <measurement group_id="O6" value="117" spread="17.4" lower_limit="12.0" upper_limit="16.5"/>
                    <measurement group_id="O7" value="153" spread="17.2" lower_limit="14.4" upper_limit="19.8"/>
                    <measurement group_id="O8" value="107" spread="17.7" lower_limit="11.6" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fractional Excretion of uric acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="13.1" lower_limit="9.82" upper_limit="13.3"/>
                    <measurement group_id="O2" value="157" spread="12.9" lower_limit="12.0" upper_limit="15.5"/>
                    <measurement group_id="O3" value="214" spread="14.5" lower_limit="15.0" upper_limit="18.8"/>
                    <measurement group_id="O4" value="214" spread="14.3" lower_limit="15.0" upper_limit="18.6"/>
                    <measurement group_id="O5" value="145" spread="15.1" lower_limit="11.1" upper_limit="14.7"/>
                    <measurement group_id="O6" value="137" spread="18.4" lower_limit="11.2" upper_limit="15.3"/>
                    <measurement group_id="O7" value="168" spread="15.5" lower_limit="13.5" upper_limit="17.6"/>
                    <measurement group_id="O8" value="120" spread="14.2" lower_limit="10.5" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <time_frame>8 weeks</time_frame>
        <population>The safety population included all participants who received any dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>RDEA3170 capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
          </group>
          <group group_id="O5">
            <title>Treatment E</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
          </group>
          <group group_id="O6">
            <title>Treatment I</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fasted state.</description>
          </group>
          <group group_id="O7">
            <title>Treatment J</title>
            <description>RDEA3170 capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
          </group>
          <group group_id="O8">
            <title>Treatmnet K</title>
            <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <population>The safety population included all participants who received any dose of investigational product.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Overall number of baseline participants used to determine number of participants at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Verinurad capsules, 5 mg (FN24), administered in the fasted state.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Verinurad capsules, 5 mg (FN24), administered in the fed state (highfat, high-calorie meal).</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Verinurad capsules, 10 mg (FN25), administered in the fasted state.</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>RDEA3170 capsules, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal)</description>
        </group>
        <group group_id="E5">
          <title>Treatment E</title>
          <description>RDEA3170 tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
        </group>
        <group group_id="E6">
          <title>Treatment I</title>
          <description>Verinurad capsules, 10 mg (FN26), administered in the fasted state.</description>
        </group>
        <group group_id="E7">
          <title>Treatment J</title>
          <description>Verinurad capsules, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).</description>
        </group>
        <group group_id="E8">
          <title>Treatment K</title>
          <description>Verinurad tablets, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jesse Hall, MD</name_or_title>
      <organization>Ardea Biosciences, Inc.</organization>
      <phone>(858) 652-6672</phone>
      <email>JHall@ardeabio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

